Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker HALO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone… NCT06689085 · Hypogonadism, Male Testosterone enanthate | HALO Halozyme Therapeutics | Phase 3 | Recruiting | 100 | Mar 2028 | Registry ↗ |
| Dec 17, 2021 | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Conta… NCT00928447 · Dermatitis, Allergic Contact rHuPH20, Placebo | HALO Halozyme Therapeutics | Phase 2 | Completed | 22 | Sep 13, 2009 | Registry ↗ |
| Oct 29, 2021 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Parti… NCT00318643 · Bladder Cancer Mitomycin C, Chemophase | HALO Halozyme Therapeutics | Phase 1/2 | Completed | 27 | Aug 11, 2009 | Registry ↗ |
| Jul 20, 2020 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Parti… NCT01839487 · Metastatic Pancreatic Cancer PEGPH20, Nab-paclitaxel | HALO Halozyme Therapeutics | Phase 2 | Completed | 279 | May 1, 2018 | Registry ↗ |
| Jul 14, 2020 | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcit… NCT02715804 · Pancreatic Ductal Carcinoma Biological: PEGylated Recombinant Human Hyaluronidase (PEGP… | HALO Halozyme Therapeutics | Phase 3 | Terminated | 492 | Nov 4, 2019 | Registry ↗ |
| Feb 7, 2020 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS… NCT03267940 · Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intr… PEGPH20, CIS | HALO Halozyme Therapeutics | Phase 1 | Terminated | 85 | Nov 11, 2019 | Registry ↗ |
| Feb 7, 2020 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants W… NCT02563548 · NSCLC, Gastric Cancer PEGPH20, Pembrolizumab | HALO Halozyme Therapeutics | Phase 1 | Completed | 56 | Mar 26, 2019 | Registry ↗ |
| Feb 26, 2019 | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Hum… NCT01526733 · Type 1 Diabetes Mellitus Sham Injection, Recombinant human hyaluronidase PH20 | HALO Halozyme Therapeutics | Phase 4 | Completed | 25 | Aug 2012 | Registry ↗ |
| Feb 26, 2019 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone… NCT01194245 · Diabetes Mellitus, Type 1 Insulin lispro, recombinant human hyaluronidase PH20 | HALO Halozyme Therapeutics | Phase 2 | Completed | 135 | Aug 2011 | Registry ↗ |
| Feb 26, 2019 | Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabete… NCT00774800 · Type 1 Diabetes Mellitus Humalog, Humulin-R | HALO Halozyme Therapeutics | Phase 2 | Completed | 22 | Mar 2009 | Registry ↗ |
| Feb 26, 2019 | Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog… NCT00705536 · Diabetes Mellitus Humalog, Humulin-R | HALO Halozyme Therapeutics | Phase 1 | Completed | 26 | Feb 2008 | Registry ↗ |
| Feb 8, 2019 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in… NCT02346370 · Non-small Cell Lung Cancer PEGylated recombinant human hyaluronidase PH20, Docetaxel | HALO Halozyme Therapeutics | Phase 1 | Terminated | 16 | Aug 9, 2016 | Registry ↗ |
| Feb 1, 2019 | A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Di… NCT03662334 · Type 1 Diabetes Mellitus Rapid Acting insulin with pre-treatment of rHuPH20, Sham in… | HALO Halozyme Therapeutics | Phase 4 | Completed | 14 | Feb 27, 2014 | Registry ↗ |
| Nov 30, 2018 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Can… NCT01453153 · Stage IV Pancreatic Cancer Gemcitabine, PEGPH20 | HALO Halozyme Therapeutics | Phase 1/2 | Completed | 28 | Feb 2014 | Registry ↗ |
| Nov 7, 2018 | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection)… NCT01848990 · Type 1 Diabetes Mellitus Commercial Hylenex® recombinant (hyaluronidase human inject… | HALO Halozyme Therapeutics | Phase 4 | Completed | 456 | Feb 2014 | Registry ↗ |
| Nov 7, 2018 | Subcutaneous Rehydration Compared to Intravenous Rehydration NCT00773175 · Dehydration recombinant human hyaluronidase | HALO Halozyme Therapeutics | Phase 4 | Completed | 148 | Nov 2009 | Registry ↗ |
| Oct 17, 2018 | Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) NCT00656370 · Healthy recombinant human hyaluronidase | HALO Halozyme Therapeutics | Phase 4 | Completed | 15 | Jan 30, 2008 | Registry ↗ |
| Aug 15, 2018 | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bi… NCT00807963 · Risk Factors for or a Diagnosis of Osteoporosis rHuPH20, zoledronic acid | HALO Halozyme Therapeutics | Phase 1 | Completed | 31 | Sep 21, 2009 | Registry ↗ |
| Aug 15, 2018 | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneou… NCT00803972 · Healthy Volunteers rHuPH20, Insulin Human Injection | HALO Halozyme Therapeutics | Phase 1 | Completed | 42 | Aug 28, 2009 | Registry ↗ |
19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances